Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee

Trial Profile

A Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined with Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2018

At a glance

  • Drugs Hyaluronic acid/triamcinolone (Primary) ; Hyaluronic acid; Triamcinolone
  • Indications Osteoarthritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Anika Therapeutics
  • Most Recent Events

    • 24 Oct 2018 According to an Anika Therapeutics media release, the company continued to work with external regulatory and legal experts to seek regulatory approval of CINGAL in the U.S. market.Anika plans to meet with the U.S. Food and Drug Administration (FDA) in the first quarter of 2019 and is developing multiple strategies to enable the company to move forward expeditiously once it has received guidance from the FDA regarding the pathway for CINGAL.
    • 19 Jun 2018 Results presented in the Anika Therapeutics media release.
    • 19 Jun 2018 According to an Anika Therapeutics media release, Prof. Laszlo Hangody is the global principal investigator of several CINGAL trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top